Selective EP4 Receptor Antagonist for Renal Failure
Solution Overview
Problem
Current pharmaceutical compositions lack an effective compound for treating chronic renal failure and diabetic nephropathy, as existing EP4 receptor antagonists have limitations in specificity and efficacy.
Innovation Solution
The compound 4-[(1S)-1-({[4-bromo-1-(isoquinolin-3-ylmethyl)-3-methyl-1H-pyrazol-5-yl]carbonyl}amino)ethyl]benzoic acid (Compound A) or its salt, which exhibits excellent EP4 receptor antagonistic action, is used in a pharmaceutical composition to prevent or treat chronic renal failure and diabetic nephropathy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing EP4 receptor antagonists are used, then some EP4 receptor activity is inhibited, but they lack sufficient specificity and efficacy for treating chronic renal failure and diabetic nephropathy
Solution Approach 1:
The compound exhibits selective antagonistic activity specifically at the EP4 receptor subtype while maintaining minimal affinity for other EP receptor subtypes (EP1, EP2, EP3). This localized specificity is achieved through the unique molecular structure featuring a pyrazole ring combined with isoquinoline and benzoic acid moieties, allowing the compound to target EP4-related diseases without causing side effects associated with off-target receptor binding
Solution Approach 2:
The compound demonstrates optimized binding parameters including a Ki value of 0.874 nmol/L for the rat EP4 receptor, indicating high affinity and potency. The molecular structure parameters were specifically designed to achieve this level of specificity and efficacy, with the compound showing 1000-fold or greater selectivity for EP4 over other EP receptor subtypes
2Reliability
If existing EP4 receptor antagonists are used, then some therapeutic effect is achieved, but they do not provide sufficient inhibition of EP4 receptor activity
Solution Approach 1:
The compound integrates multiple functional molecular moieties into a single composite structure: a pyrazole ring (providing core scaffold), isoquinoline group (enhancing receptor affinity), and benzoic acid moiety (contributing to binding orientation). This composite molecular architecture achieves potent and selective EP4 receptor antagonism with a Ki value of 0.874 nmol/L, providing superior therapeutic efficacy for chronic renal failure and diabetic nephropathy
Data Source
AI summary
A compound which is useful as an active ingredient of a pharmaceutical composition, for example, a pharmaceutical composition for treating chronic renal failure and/or diabetic nephropathy is provided.



